Michela Verze
Parma, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
A radiomic approach to non-invasively decode tumor immune microenvironmental features in surgically resected non-small cell lung cancer.
Journal: Tumori
Published: August 12, 2026
Liquid Biopsy Monitoring in BRAF V600E-Mutated Patients With Non-Small Cell Lung Cancer Treated With Dabrafenib Plus Trametinib: The Prospective, Multicenter LiBRA Study (GOIRC-03-2020).
Journal: JCO precision oncology
Published: June 12, 2026
Clinical significance of EGFR amplification in patients with EGFR-mutated metastatic non-small cell lung cancer receiving first-line osimertinib.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 06, 2026
Dissecting the impact of Controlling Nutritional Status (CONUT) score on survival outcomes and immune-inflammatory profiles in patients with advanced NSCLC undergoing first-line immunotherapy.
Journal: Journal for immunotherapy of cancer
Published: December 15, 2025
BRAF Fusion as Resistance Mechanism to Osimertinib in EGFR-Mutated NSCLC: A Case Report and Review of Literature.
Journal: JTO clinical and research reports
Published: February 26, 2025
MET alterations as resistance mechanisms of dabrafenib-trametinib in BRAF p.V600E mutated non-small cell lung cancer patient.
Journal: Anti-cancer drugs
Published: August 08, 2024
Liquid Biopsy and 18F-FDG PET/CT Derived Parameters as Predictive Factors of Osimertinib Treatment in Advanced EGFR-Mutated NSCLC.
Journal: Clinical lung cancer
Published: May 15, 2024
NGS detection of gene rearrangements and METexon14 mutations in liquid biopsy of advanced NSCLC patients: A study of two Italian centers.
Journal: The journal of liquid biopsy
Published: January 24, 2024
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors.
Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)
Published: January 23, 2024
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 18, 2023
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models.
Journal: Scientific reports
Published: October 05, 2023
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies.
Journal: British journal of cancer
Published: February 24, 2023
Last Updated: 09/26/2026